top of page
The Professional Network for Healthcare Experts
FDA grants final approval to Bravnetsa for SSTR-positive GEP-NETs
The FDA has granted final approval to Lantheus' Bravnetsa for adults with somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumours.
nuaxia
Sep 231 min read
Novartis licenses BoomRay radioligand therapy in deal worth up to $900m
Novartis has secured exclusive worldwide rights to an undisclosed preclinical radioligand therapy from BoomRay Pharma in a licensing agreement worth up to $900 million.
nuaxia
Sep 232 min read
Telix and ITM agree $1.65bn radiopharmaceutical merger
Telix Pharmaceuticals has agreed to acquire ITM in a major radiopharmaceutical transaction valued at $1.65 billion upfront, with up to a further $700 million linked to regulatory and commercial milestones.
nuaxia
Sep 212 min read
FDA approves Curium's Bexlutry as first radioligand equivalent for SSTR-positive GEP-NETs
The FDA has approved Curium's Bexlutry as the first radioligand equivalent to Lutathera for adults with somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumours.
nuaxia
Sep 161 min read
bottom of page